Akebia Therapeutics (AKBA) EBIT Margin (2017 - 2026)
Akebia Therapeutics (AKBA) posted quarterly EBIT Margin of 8.77% for Q1 2026, down 3234.0% year-over-year from 0.28% in Q1 2025, and up 40.91% quarter-over-quarter from 14.84% in Q4 2025.
Akebia Therapeutics (AKBA) EBIT Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported EBIT Margin for 10 consecutive years, with 8.77% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 3234.0% year-over-year to 8.77%; the TTM figure through Mar 2026 stood at 2.28% (up 1419.0% YoY), while the FY2025 annual figure was 9.95%, up 4146.0% from the prior year.
- EBIT Margin advanced to 8.77% in Q1 2026 per AKBA's latest filing, from 14.84% in the prior quarter.
- Across five years, EBIT Margin topped out at 26.97% in Q2 2022 and bottomed at 78396.05% in Q1 2022.
- Historically, EBIT Margin has averaged 4628.8% across 5 years, with a median of 15.96% in 2023.
- Annual changes were most pronounced in 2022 — EBIT Margin slumped 7827190 bps — and 2023, when it surged 7833207 bps.
- Akebia Therapeutics' EBIT Margin stood at 8.73% in 2022, then surged by 128 bps to 2.45% in 2023, then plunged by 1358 bps to 30.77% in 2024, then surged by 52 bps to 14.84% in 2025, then surged by 41 bps to 8.77% in 2026.
- Business Quant data shows AKBA's EBIT Margin at 8.77% in Q1 2026, 14.84% in Q4 2025, and 7.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -12.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.88% |
| Mar 31, 2026 | -8.77% |
| Dec 31, 2025 | -14.84% |
| Sep 30, 2025 | 7.57% |
| Jun 30, 2025 | 22.55% |
| Mar 31, 2025 | 23.57% |
| Dec 31, 2024 | -30.77% |
| Sep 30, 2024 | -33.41% |
| Jun 30, 2024 | -19.99% |
| Mar 31, 2024 | -45.81% |
| Dec 31, 2023 | 2.45% |
| Sep 30, 2023 | -31.00% |
| Jun 30, 2023 | -15.96% |
| Mar 31, 2023 | -63.98% |
| Dec 31, 2022 | -8.73% |
| Sep 30, 2022 | -103.47% |
| Jun 30, 2022 | 26.97% |
| Mar 31, 2022 | -78,396.05% |
| Dec 31, 2021 | 42.97% |
| Sep 30, 2021 | -112.57% |